ConductScience.org, home

Paper39100673

A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants.

Guselnikov SV and 22 others. Front Immunol, 2024. Cited by 2 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants. Papers, record 39100673. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39100673

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants.
PubMed
Journal
Front Immunol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.17, provisional
iCite
Revised in PubMed
2026-10-16
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Guselnikov SVSergey V
2Baranov KOKonstantin O
3Kulemzin SVSergey V
4Belovezhets TNTatyana N
5Chikaev ANAnton N
6Murasheva SVSvetlana V
7Volkova OYOlga Y
8Mechetina LVLudmila V
9Najakshin AMAlexander M
10Chikaev NANikolai A
11Solodkov PPPavel P
12Sergeeva MVMaria V
13Smirnov AVAlexander V
14Serova IAIrina A
15Serov OLOleg L
16Markhaev AGAlexander G
17Kononova YVYulia V
18Alekseev AYAlexander Y
19Gulyaeva MAMarina A
20Danilenko DMDaria M

Source PubMed

See all 23 authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
SARS-CoV-2Major topic
COVID-19Major topic
Mice, TransgenicMajor topic
Angiotensin-Converting Enzyme 2Major topic
Antibodies, ViralMajor topic
Antibodies, MonoclonalMajor topic
Antibodies, NeutralizingMajor topic
Animals
Humans
Mice
Spike Glycoprotein, Coronavirus
Pandemics
Broadly Neutralizing Antibodies
Disease Models, Animal

Source PubMed

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,990,214Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.Science2022https://conductscience.org/library/papers/34990214PubMed
232,454,512A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.Nature2020https://conductscience.org/library/papers/32454512PubMed
332,422,645Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature2020https://conductscience.org/library/papers/32422645PubMed
436,319,593Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.J Med Virol2023https://conductscience.org/library/papers/36319593PubMed
536,493,787Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents.Cell Rep2022https://conductscience.org/library/papers/36493787PubMed
634,261,126SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.Nature2021https://conductscience.org/library/papers/34261126PubMed
733,436,577A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.Nat Commun2021https://conductscience.org/library/papers/33436577PubMed
817,996,249Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning.J Immunol Methods2008https://conductscience.org/library/papers/17996249PubMed
938,109,919Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.Lancet Infect Dis2024https://conductscience.org/library/papers/38109919PubMed
1033,820,835The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.Sci Transl Med2021https://conductscience.org/library/papers/33820835PubMed
1137,219,999Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination.Cell Rep2023https://conductscience.org/library/papers/37219999PubMed
1232,805,021CoV-AbDab: the coronavirus antibody database.Bioinformatics2021https://conductscience.org/library/papers/32805021PubMed
1338,302,341SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences.Trends Immunol2024https://conductscience.org/library/papers/38302341PubMed
1432,540,901Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.Science2020https://conductscience.org/library/papers/32540901PubMed
1515,035,025SARS--beginning to understand a new virus.Nat Rev Microbiol2003https://conductscience.org/library/papers/15035025PubMed
1637,845,314SARS-CoV-2 evolution in the Omicron era.Nat Microbiol2023https://conductscience.org/library/papers/37845314PubMed
1735,568,025LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.Cell Rep2022https://conductscience.org/library/papers/35568025PubMed
1838,400,113Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies.Vaccines (Basel)2024https://conductscience.org/library/papers/38400113PubMed
1935,081,335SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.Cell2022https://conductscience.org/library/papers/35081335PubMed
2036,580,913Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.Cell2023https://conductscience.org/library/papers/36580913PubMed

See all 42 references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
41,874,023Discovery of Anti-SARS-CoV-2 XBB.1.5 and JN.1 Variant-Specific Monoclonal Single-Domain Antibodies from a Synthetic Library.Antibodies (Basel)2026https://conductscience.org/library/papers/41874023

Source PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
H19-ICR105,259,599PubTator's text mininghttps://conductscience.org/library/genes/105259599

Source NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39100673

GET https://conductscience.org/api/papers/v1/39100673/authors?page=2